NCT07067268View on ClinicalTrials.gov

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

September 14, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2029

Conditions
Nasopharyngeal Cancinoma (NPC)
Interventions
DRUG

Adjuvant therapy

Tislelizumab: 200 mg IV on day 1, every 3 weeks Capecitabine: 1000 mg/m² orally twice daily on days 1-14，every 3 weeks Treatment duration: 8 cycles

Trial Locations (1)

200032

RECRUITING

Fudan Universtiy Shanghai Cancer Centre, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER